The investigators reviewed epidemiological, clinical and laboratory information from medical records and tested serum samples using a qualitative lateral-flow cryptococcal antigen assay. The sample included 63 patients, of whom 77.8% were men. Median age was 38 years, median CD4+ cell count was 33 cells/µL, with an interquartile range of 12.5–85.5, and the median logarithmic viral load was 4.95, with an interquartile range of 4.21–5.53. Among patients with CD4+ counts below 100 cells/µL, antigenemia was detected in four of 47, or 8.5%.

Six antigen-positive patients underwent lumbar puncture for cerebrospinal fluid collection. Cryptococcal meningitis was confirmed in one of them, representing 16.7% of those tested, while another patient had disseminated cryptococcal disease. Isolated cryptococcal antigenemia, without evidence of cryptococcal disease, was identified in five patients, or 7.9% of the full study population. The abstract reports that two patients died during hospitalization without evidence of cryptococcal disease. Two asymptomatic patients received fluconazole as pre-emptive treatment, and one received no antifungal drugs; none developed cryptococcal meningitis during the 12 months after discharge.

These results are limited to the small, single-hospital retrospective sample and the follow-up reported in the abstract. The study did not assess a broader population, and the absence of cryptococcal meningitis during follow-up applies only to the three antigen-positive patients whose discharge treatment was described. The authors concluded that cryptococcal antigen screening should be available for all patients in regions where the burden of cryptococcal disease among people living with HIV is high. The findings support that conclusion for the setting studied, but the abstract does not provide data on screening uptake, diagnostic delays, barriers to care or the effectiveness of screening across other hospitals or regions.

Subject of Research: Prevalence and management of cryptococcal antigenemia in hospitalized patients with advanced HIV in Ceará, Brazil

Article Title: Prevalence and management of cryptococcal antigenemia in hospitalized patients with advanced HIV infection in a tertiary hospital from Fortaleza, Ceará, Brazil between 2020 and 2022

Article References: Damasceno, L. S., Almeida Júnior, A. M. B. D., Brito, J. D. N., Maciel, L. S., Magalhães, L. F., & Mesquita, J. R. L. D. (2026). Prevalence and management of cryptococcal antigenemia in hospitalized patients with advanced HIV infection in a tertiary hospital from Fortaleza, Ceará, Brazil between 2020 and 2022. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14554-2

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14554-2

Keywords: cryptococcal antigenemia, advanced HIV, cryptococcal meningitis, hospital epidemiology, Ceará, Fortaleza, serum screening, in-hospital mortality, retrospective study, Prevalence, management, cryptococcal

The patient initially experienced prolonged constitutional symptoms, including fever, weight loss and malaise. These symptoms were followed by progressive neurological deterioration, with headache, altered mental status and signs of raised intracranial pressure. The report notes that tuberculous meningitis and cryptococcal meningitis have overlapping clinical features, creating diagnostic and therapeutic challenges when both infections are present.

Cerebrospinal fluid analysis supported a dual diagnosis. A positive GeneXpert result identified Mycobacterium tuberculosis, while cryptococcal antigen testing was consistent with Cryptococcus neoformans infection. The patient was described as HIV-negative and had no known immunosuppressive condition. The report characterizes simultaneous central nervous system infections caused by these pathogens as exceedingly rare, particularly in immunocompetent individuals.

Following diagnosis, appropriate antituberculous therapy and antifungal treatment were initiated. Nevertheless, the woman’s clinical condition continued to worsen. The case report does not provide sufficient information in the supplied account to determine whether a particular treatment regimen, the concurrent infections or other factors contributed to the fatal outcome. It therefore should not be read as evidence that either infection was untreatable or that any specific treatment caused the outcome.

During the clinical course, the patient developed communicating hydrocephalus, accompanied by intracranial pressure that remained elevated. Her neurological deterioration ultimately progressed to brain herniation and death. Hydrocephalus and raised intracranial pressure are therefore documented features of this presentation, but the supplied report does not detail the imaging or clinical measurements used to characterize them.

The authors emphasize the need for a high index of suspicion for dual infections in settings where tuberculosis and cryptococcosis occur. The case illustrates that symptoms compatible with either form of meningitis may accompany coinfection, making laboratory evidence important for establishing the diagnosis. In this patient, cerebrospinal fluid testing supported the presence of both pathogens rather than a single infectious cause.

The report also identifies multidisciplinary management and timely neurosurgical intervention as potentially important in cases accompanied by hydrocephalus and raised intracranial pressure. This is presented as a general implication of the case, not as evidence that a particular coordinated team or intervention was delivered in this patient. The supplied account does not establish the timing, type or outcome of any neurosurgical procedure.

As a single-patient case report, the research has a narrow evidentiary scope. It cannot determine the incidence of concurrent tuberculous and cryptococcal meningitis, identify the immune mechanisms or predisposing factors that permit coinfection, or compare management strategies. Its principal reported value is to document severe dual CNS infection with fatal hydrocephalus in an HIV-negative patient without a known immunosuppressive condition, while showing the diagnostic difficulty created by overlapping clinical features.

Subject of Research: Fatal concurrent tuberculous and cryptococcal meningitis with hydrocephalus in an HIV-negative patient

Article Title: Concurrent tuberculous and cryptococcal meningitis with hydrocephalus in an HIV- negative patient: a fatal case report

Article References: Tesfaye, M. Z., Gebretekle, F. T., Mered, E. F., Talemahu, A. A., & Kassie, H. T. (2026). Concurrent tuberculous and cryptococcal meningitis with hydrocephalus in an HIV- negative patient: a fatal case report. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14455-4

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14455-4

Keywords: tuberculous meningitis, cryptococcal meningitis, concurrent infections, HIV-negative patient, hydrocephalus, intracranial pressure, cerebrospinal fluid, case report, Concurrent, tuberculous, cryptococcal, meningitis

The research team, led by investigators including Maura Manion, Camille M. Lange, and Frank Maldarelli, analyzed paired samples of blood plasma and cerebrospinal fluid from thirty-nine people with HIV-1 who had active cryptococcal meningitis. All samples were collected before the participants began antiretroviral therapy, providing a snapshot of viral dynamics during a period of uncontrolled replication. Across the cohort, HIV-1 viral loads in plasma were significantly higher than those measured in cerebrospinal fluid, a pattern consistent with the blood serving as the primary reservoir of viral production. Yet the relationship between the two compartments was not uniform, and the differences that did emerge pointed to distinct mechanisms shaping viral populations behind the blood-brain barrier.

One of the clearest signals came from participants who exhibited pleocytosis, an elevated white cell count in the cerebrospinal fluid that indicates active inflammation within the central nervous system. Among these individuals, viral loads in the cerebrospinal fluid were relatively higher, and the viruses detected there more frequently used CCR5 as their coreceptor for entry into host cells. Coreceptor usage is a defining feature of HIV-1 biology: viruses that prefer CCR5 are typically associated with early infection and macrophage tropism, while those that shift toward CXCR4 tend to emerge later and target T cells more efficiently. The enrichment of CCR5-utilizing variants in inflamed cerebrospinal fluid suggests that the local environment during cryptococcal meningitis favors particular viral phenotypes, possibly because activated macrophages and microglia provide abundant CCR5-expressing targets in an inflamed brain.

To determine whether these differences reflected sustained HIV-1 replication within the central nervous system that generated genetically distinct viral lineages, a phenomenon known as viral compartmentalization, the researchers conducted a deeper genetic analysis in a subgroup of eighteen participants. Nine of these had cerebrospinal fluid HIV-1 RNA levels exceeding those in blood, while the other nine had cerebrospinal fluid levels below blood levels. The team sequenced the viral env gene, which encodes the envelope glycoprotein responsible for host cell entry, from viruses in both compartments and compared the resulting phylogenetic relationships.

Compartmentalization between cerebrospinal fluid and plasma viral populations was detected in participants from both groups, demonstrating that genetically distinct viral populations can establish themselves in the central nervous system regardless of whether cerebrospinal fluid viral loads are higher or lower than those in blood. Notably, this compartmentalization was associated with higher levels of interleukin-2 in the cerebrospinal fluid, linking the genetic separation of viral populations to the local cytokine milieu. Interleukin-2 is a signaling molecule that promotes T cell proliferation and survival, and its elevation in the cerebrospinal fluid may reflect the kind of immune activation that supports localized viral replication and evolution behind the blood-brain barrier.

The study revealed striking heterogeneity in the mechanisms that populate the central nervous system with HIV-1 during cryptococcal meningitis. In some participants, the viruses found in cerebrospinal fluid were compartmentalized from those in plasma, were exclusively macrophage-tropic, and reached concentrations exceeding 100,000 copies per milliliter of cerebrospinal fluid. This profile is consistent with sustained local replication in macrophages or microglia within the brain, producing a viral lineage adapted to that niche and largely disconnected from the circulating population. In other participants, however, the pattern suggested a different origin: HIV-1 infected cells trafficking between the plasma and cerebrospinal fluid compartments appeared to be the most likely source of the virus detected in the cerebrospinal fluid. In these cases, the central nervous system was not an independent viral sanctuary but rather a destination for infected cells migrating from the periphery.

The researchers also gained a glimpse into how these dynamics evolve after treatment begins. Post-antiretroviral therapy analysis in one participant demonstrated the emergence of distinct HIV-1 populations, indicating that the selective pressures exerted by therapy and the changing immune environment can reshape viral lineages in ways that differ between blood and brain. While the study examined this transition in only a single participant, the observation underscores that the viral populations established during active cryptococcal meningitis may have consequences that persist into the treatment era.

These findings carry significant implications for understanding HIV-1 persistence in the central nervous system and for managing neurological complications in people living with the virus. The central nervous system has long been recognized as a potential reservoir where HIV-1 can replicate independently of the blood, sheltered by the blood-brain barrier and sustained by long-lived myeloid cells such as macrophages and microglia. Cryptococcal meningitis, by compromising that barrier and driving intense inflammation, appears to create conditions that can either foster the emergence of locally adapted, macrophage-tropic viral lineages or facilitate the traffic of infected cells across compartments. The direction a given infection takes may depend on host factors such as the degree of pleocytosis and cytokine profiles, as well as on viral factors including coreceptor preference and cellular tropism.

The diversity of outcomes observed in this cohort challenges the notion that opportunistic infections of the brain act on HIV-1 in a single, predictable way. Instead, the study demonstrates that cryptococcal meningitis may have diverse effects in shaping HIV-1 viral populations, with some individuals developing compartmentalized, macrophage-tropic reservoirs in the central nervous system while others carry viruses that simply reflect ongoing exchange with the blood. As antiretroviral therapy suppresses plasma viremia in most treated individuals, understanding which patients harbor independently evolving central nervous system populations becomes increasingly important for efforts aimed at viral eradication and for explaining cases of neurological disease that persist despite effective systemic treatment. The work also highlights the value of studying HIV-1 in the context of real-world coinfections, which remain common in the regions most affected by the epidemic and may leave lasting imprints on the viral landscape that outlive the infection itself.

Subject of Research: HIV-1 compartmentalization in the central nervous system during cryptococcal meningitis

Article Title: HIV-1 compartmentalization in the central nervous system during cryptococcal meningitis: Analysis of viral, fungal, and host factors

Article References: Manion, M., Lange, C. M., Ortega-Villa, A. M., Fennessey, C. M., Keele, B. F., Moeser, M., Highbarger, H., Huik, K., Lindo, N., Gonsalves, C., Virga, J., Meya, D. B., Joseph, S. B., Boulware, D. R., Sereti, I., & Maldarelli, F. (2026). HIV-1 compartmentalization in the central nervous system during cryptococcal meningitis: Analysis of viral, fungal, and host factors. PLOS Pathogens, 22(10), e1014697. https://doi.org/10.1371/journal.ppat.1014697

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014697

Keywords: HIV-1, cryptococcal meningitis, central nervous system, viral compartmentalization, PLOS Pathogens, macrophage-tropic HIV, blood-brain barrier, cerebrospinal fluid, compartmentalization, central, nervous, system

Inositol occupies a peculiar place in the biology of C. neoformans. Most microbes treat the molecule, a six-carbon cyclic sugar alcohol abundant in the mammalian brain, as little more than an occasional nutrient. This yeast, by contrast, has evolved the capacity to use inositol both as a signaling cue and as a genuine carbon source, a dual utility that serves it in the soil, in the environment at large, and inside its human host. High concentrations of free inositol in brain tissue have long been suspected of luring the fungus toward the central nervous system, helping to explain why C. neoformans shows such a striking tropism for that organ. The new work now reveals the receptor at the top of this sensing cascade, and it turns out to be a far more elaborate player than a simple transporter.

The team identified Itr4 as an inositol transporter-like protein that functions as a transceptor, a hybrid molecule that combines the architecture of a membrane transporter with the signaling behavior of a receptor. Transceptors are well known in bacteria and in yeasts such as Saccharomyces cerevisiae, where nutrient transporters double as sensors that inform the cell about the state of the environment. But Itr4 is the first example of an inositol transceptor documented in any eukaryote, and its regulatory reach is unusually broad. Rather than merely reporting the presence of inositol, Itr4 coordinates inositol and glucose metabolism together, governing the function of other inositol transporters, collectively known as ITRs, and of Hxs1, the fungal glucose sensor. This places a single membrane protein at the junction of two nutrient-sensing pathways that were previously studied in isolation.

The experimental evidence for this dual role came from a combination of genetic and biochemical approaches. The researchers showed that Itr4 physically binds inositol, confirming that the protein is a genuine receptor for the sugar rather than an incidental bystander. They then demonstrated that Itr4 regulates the activity of the other inositol transporters in the fungal membrane, effectively acting as a conductor that tunes how much inositol the cell imports. When the ITR4 gene was deleted, the fungus suffered a significant drop in inositol uptake activity, and the consequences rippled outward through the organism’s biology in ways that matter enormously for disease.

Those consequences read like a checklist of the traits that make C. neoformans dangerous. Fungal cells lacking Itr4 failed to mate, losing the sexual reproduction cycle that depends on inositol signaling and that contributes to genetic diversity and spore formation in the environment. They produced smaller capsules, the polysaccharide halo that shields the yeast from immune attack and is one of its principal virulence factors. Most strikingly, they showed reduced penetration of the blood–brain barrier, the dense cellular wall that protects the central nervous system and that the wild-type fungus crosses with alarming efficiency. The net result was a marked attenuation of virulence, meaning that a strain missing this single receptor could no longer cause disease with the same lethal effectiveness. In other words, a protein built to sense a dietary sugar turns out to be a linchpin of pathogenesis.

To understand how Itr4 performs its regulatory duties, the team turned to mutagenesis, systematically altering the protein’s amino acid sequence to map the regions that carry functional weight. This analysis identified an essential N-terminal tail, the segment at the beginning of the protein that protrudes into the cell’s interior, as indispensable for Itr4’s role. It also pinpointed two adjacent amino acids, glutamine 388 and glutamine 389, as sites of particular functional importance. These residues sit within the membrane-spanning portion of the protein, and their substitution produced effects that were anything but a simple loss of function.

The mutant allele carrying alanine substitutions at those two positions, designated ITR4^(Q388A, Q389A), displayed a dominant phenotype that surprised the investigators. Cells carrying this allele took up more inositol than normal, grew enlarged capsules, and yet were significantly attenuated in virulence. The combination is counterintuitive: a bigger capsule is usually associated with a more formidable pathogen, and elevated inositol uptake might be expected to enhance rather than weaken fitness. The finding suggests that the relationship between inositol metabolism and virulence is not a simple linear one, and that Itr4’s regulatory function, its ability to coordinate the wider network of transporters and sensors, matters as much as the raw quantity of sugar entering the cell. When that coordination is disrupted, the fungus becomes dysregulated in ways that ultimately compromise its ability to cause disease, even as some individual traits appear exaggerated.

The broader significance of the work lies in what it reveals about how pathogens integrate environmental sensing with metabolic decision-making. Carbon catabolite regulation, the system by which microbes prioritize one carbon source over another, is a foundational process in microbiology, and glucose has traditionally occupied the center of that picture. The demonstration that an inositol receptor sits at the heart of carbon catabolite regulation in C. neoformans, simultaneously controlling inositol transporters and the glucose sensor Hxs1, expands the conceptual framework. It shows that in this fungus, a molecule abundant in the mammalian brain is not merely food but a regulatory signal woven into the very machinery that governs how the cell chooses its fuels. That integration appears to be what allows the yeast to flourish in environments as different as decaying plant matter, pigeon droppings, human blood and brain tissue.

For the field of fungal pathogenesis, Itr4 offers both a conceptual advance and a practical lead. Virulence in C. neoformans has been dissected through many angles, from the capsule and the pigment melanin to the enzymes that degrade host tissue, but nutrient-sensing receptors have rarely been placed so directly at the center of the virulence program. The fact that loss of Itr4 attenuates the fungus, and that a two-amino-acid mutation can decouple capsule growth from virulence, suggests that the receptor’s signaling function could be a plausible target for therapeutic intervention. Drugs that disrupt Itr4’s regulatory activity, or that mimic the dysregulation seen in the Q388 and Q389 mutants, might strip the fungus of its ability to coordinate metabolism during infection without needing to kill the organism outright, a strategy that could be valuable given the limited arsenal of antifungal drugs and their significant toxicity.

There are also evolutionary implications worth savoring. The existence of an inositol transceptor in a basidiomycete yeast hints that nutrient receptor biology is more diverse across the fungal kingdom than the models built on baker’s yeast would suggest. Because inositol is a dominant small solute in the brain, a pathogen that can both consume it and respond to it has effectively tuned its metabolism to the chemistry of its target organ. The work by Wang and colleagues makes clear that this tuning is not accidental but orchestrated, with Itr4 standing at the switchboard, binding its sugar ligand and broadcasting the news to the transporters and sensors that decide what the cell will eat, how large its defenses will grow, and whether it will make the journey across the blood–brain barrier into the one organ where cryptococcal infection is most devastating.

Subject of Research: An inositol receptor Itr4 coordinates carbon catabolite regulation and virulence in Cryptococcus neoformans

Article Title: An inositol receptor Itr4 coordinates carbon catabolite regulation and virulence in Cryptococcus neoformans

Article References: Wang, Y., Tancer, R., Wear, M., Jackson, K. M., Zhang, Y., Li, K., Wang, J., Gao, Y.-G., Nielsen, K., Casadevall, A., & Xue, C. (2026). An inositol receptor Itr4 coordinates carbon catabolite regulation and virulence in Cryptococcus neoformans. PLOS Biology, 24(10), e3003709. https://doi.org/10.1371/journal.pbio.3003709

Image Credits: AI Generated

DOI: 10.1371/journal.pbio.3003709

Keywords: inositol, receptor, Itr4, coordinates, carbon, catabolite, regulation, virulence, Cryptococcus, neoformans, scientific research

The study, led by Rhona C. B. Muyise and Samuel Jjunju of the Infectious Diseases Institute at Makerere University, together with collaborators at the University of Minnesota and other institutions, was designed as a post-hoc analysis of a prospective cohort assembled from the ASTRO, AMBITION, ENACT, and FLOOR clinical trials. Of 1,055 participants diagnosed with cryptococcal meningitis across these trials, 787 survived their initial hospitalization and could be followed for more than ten weeks after discharge. This large, carefully characterized population allowed the investigators to measure not only how often rehospitalization occurred, but why it occurred and what it meant for survival—questions that have remained largely unanswered despite substantial advances in the treatment of cryptococcal disease itself.

The technical details of the cohort underscore how profoundly immunocompromised these patients were. The median CD4 cell count at baseline was just 21 cells per microliter of blood, with an interquartile range of 8 to 58—a level of immune depletion at which the body’s defenses against fungal pathogens are essentially absent. Only 45 percent of participants had prior experience with antiretroviral therapy, meaning that more than half were starting HIV treatment for the first time while simultaneously battling a life-threatening fungal infection of the brain and its surrounding membranes. Cryptococcal meningitis is caused by Cryptococcus neoformans and related species, environmental yeasts that people inhale routinely but that cause disease almost exclusively in severely immunosuppressed individuals.

The headline numbers are stark. Within ten weeks of discharge, 17 percent of the 787 survivors—133 patients—were rehospitalized at least once, and 13 percent—101 patients—died. These categories overlapped in important ways: among the 654 participants who did not report rehospitalization, 11.6 percent, or 76 patients, nevertheless died by the ten-week mark without ever returning to hospital. Among the 133 who were rehospitalized, 18 percent, or 25 patients, died during or after that readmission. The median time from initial discharge to rehospitalization was 20 days, with an interquartile range of 10 to 36 days, meaning that half of all readmissions occurred within roughly three weeks of discharge—a period when many patients in resource-limited settings have limited access to follow-up care.

Perhaps the most clinically valuable contribution of the study is its systematic accounting of why patients returned to hospital. The researchers classified the reasons for all 133 rehospitalizations and found that the largest share—92 cases—stemmed from meningitis-related causes: culture-positive relapse of the original cryptococcal infection, paradoxical immune reconstitution inflammatory syndrome, or elevated intracranial pressure. Each of these mechanisms reflects a distinct biological problem. Relapse occurs when viable fungi persist despite antifungal therapy, often because induction treatment was inadequate or adherence lapsed. Paradoxical immune reconstitution inflammatory syndrome, or IRIS, is the inflammatory storm that can erupt when antiretroviral therapy restores immune function and the revived immune system mounts an exuberant response to residual fungal antigens in the central nervous system. Elevated intracranial pressure, a hallmark of cryptococcal meningitis, can persist or recur even after microbiological cure, causing severe headaches, vision loss, and neurological deterioration that require repeated lumbar punctures to relieve.

Beyond the brain, the readmission diagnoses read like a catalogue of advanced AIDS and its complications. Tuberculosis accounted for 26 rehospitalizations, other opportunistic infections for 39, and malignancy for 9. Hematologic disorders, including anemia and cytopenias, drove 21 admissions, while kidney and electrolyte disorders—conditions that can arise from both HIV-associated nephropathy and the nephrotoxic effects of amphotericin-based antifungal regimens—accounted for 29. Another 23 admissions were attributed to other conditions. The breadth of this list is itself a finding: patients surviving cryptococcal meningitis are not merely at risk of their index infection recurring, but remain extraordinarily vulnerable to the full spectrum of AIDS-defining and treatment-related complications during the fragile weeks after discharge.

In an effort to identify who was most likely to be readmitted, the investigators performed statistical analyses of potential risk factors, and the results were unexpectedly null. No baseline characteristic reliably predicted rehospitalization. This absence of identifiable risk factors carries its own clinical message: readmission risk appears to be distributed broadly across the survivor population rather than concentrated in a recognizable high-risk subgroup. In practical terms, clinicians cannot easily single out which discharged patients warrant the most intensive follow-up on the basis of demographic or clinical features alone, which argues for structured post-discharge monitoring for all survivors rather than targeted surveillance of a presumed vulnerable minority.

Where the analysis did find signal was in mortality. Older age was associated with an increased risk of death during the post-discharge period, while two factors were protective: higher body weight and higher Glasgow Coma Scale scores at baseline. The Glasgow Coma Scale, a standard measure of consciousness and neurological function, is already used to stratify severity in cryptococcal meningitis, and its protective association here confirms that patients discharged with better neurological status fare better. The protective effect of higher weight likely reflects overall nutritional reserve and illness severity—patients who are more wasted by advanced HIV disease and prolonged infection have less physiological buffer against subsequent complications. These mortality associations, unlike the rehospitalization analysis, offer concrete variables that clinicians can incorporate into discharge counseling and triage decisions.

The study’s implications reach well beyond Uganda. Cryptococcal meningitis kills an estimated 180,000 people annually worldwide, with the overwhelming burden in sub-Saharan Africa, and even with newer, more effective and better-tolerated regimens such as the single-dose amphotericin strategy validated in the AMBITION trial, survival after hospital discharge has remained poorly characterized. By demonstrating that a quarter of survivors experience rehospitalization or death within ten weeks, the study reframes the post-discharge period as a distinct phase of care deserving its own clinical infrastructure—structured follow-up visits, early antiretroviral therapy initiation with careful IRIS monitoring, screening for tuberculosis and other opportunistic infections, and management of intracranial pressure. The work also highlights the value of linking large clinical trial cohorts to longitudinal outcomes: because the four trials enrolled participants prospectively with standardized follow-up, the researchers could capture readmissions and deaths with a completeness that routine hospital records rarely allow.

For a disease that has seen genuine therapeutic progress over the past decade, the persistence of this post-discharge crisis is a reminder that antifungal drug regimens, however improved, address only part of the problem. The patients in this cohort left the hospital with CD4 counts in the low double digits, often newly started on antiretroviral therapy, and facing a landscape of competing infectious, inflammatory, renal, hematologic, and malignant threats. The Ugandan team’s data make clear that the ten weeks after discharge are not a quiet convalescence but a high-stakes transition, and that health systems serving populations with advanced HIV disease must plan for it accordingly. Whether interventions such as enhanced follow-up clinics, pre-emptive treatment of residual fungal burden, or earlier detection of IRIS and tuberculosis can bend this curve is now the pressing question the study leaves for the field.

Subject of Research: Rehospitalization and post-discharge outcomes among adults with HIV-related cryptococcal meningitis in Uganda

Article Title: Incidence, reasons, and outcomes of rehospitalization among adults with HIV-related cryptococcal meningitis in Uganda: a post-hoc analysis of a prospective cohort

Article References: Muyise, R. C. B., Jjunju, S., Kwizera, R., Dai, B., Adzemovic, T., Mufti, S. S., Meya, D. B., & Boulware, D. R. (2026). Incidence, reasons, and outcomes of rehospitalization among adults with HIV-related cryptococcal meningitis in Uganda: a post-hoc analysis of a prospective cohort. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14594-8

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14594-8

Keywords: cryptococcal meningitis, HIV, AIDS, rehospitalization, mortality, Uganda, immune reconstitution inflammatory syndrome, tuberculosis, intracranial pressure, CD4 count, antiretroviral therapy, BMC Infectious Diseases